Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?
Antimicrob Agents Chemother
.
2021 May 18;65(6):e00430-21.
doi: 10.1128/AAC.00430-21.
Print 2021 May 18.
Authors
Ruth Van Daele
1
2
,
Yves Debaveye
3
4
,
Katrien Lagrou
5
6
7
,
Isabel Spriet
8
2
Affiliations
1
Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
2
Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.
3
Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
4
Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.
5
Clinical Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
6
National Reference Centre for Mycosis, Excellence Centre for Medical Mycology (ECMM), University Hospitals Leuven, Leuven, Belgium.
7
Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
8
Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
[email protected]
.
PMID:
33782011
PMCID:
PMC8316108
DOI:
10.1128/AAC.00430-21
No abstract available
Keywords:
antifungals; candidemia; critically ill; exposure; invasive candidiasis; pharmacokinetics.
Publication types
Letter
Comment
MeSH terms
Candidiasis, Invasive*
Critical Illness
Fluconazole* / therapeutic use
Humans
Substances
Fluconazole